{"metadata": {"source": "psychonaut", "title": "Fentanyl - PsychonautWiki", "description": "Fentanyl (also known as Fentanil and by the brand names Sublimaze,[2] Actiq, Durogesic, Duragesic, Fentora, Matrifen, Haldid, Onsolis, Instanyl,[3] Abstral,[4] Lazanda[5] among others[6]) is a potent opioid substance of the anilidopiperidine class. It is a strong agonist at the μ-opioid receptors and approximately 40 to 50 times more potent than pharmaceutical grade (i.e. 100% pure) heroin[7][8] and roughly 80 to 100 times more potent than morphine.&#91;citation needed&#93;", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/Fentanyl", "drug": "Fentanyl", "cid": 3345, "char_count": 24990, "word_count": 3519, "doc_id": "doc_75", "num_chunks": 35, "chunk_id": "75::chunk_31", "document_index": 75, "latency_s": 0.7547820000036154, "prompt_toks": 6422, "completion_toks": 64, "relevance_score": 0.00058155763}, "content": "Drug: Fentanyl | cid: 3345\nSource: psychonaut | Source description: Fentanyl (also known as Fentanil and by the brand names Sublimaze,[2] Actiq, Durogesic, Duragesic, Fentora, Matrifen, Haldid, Onsolis, Instanyl,[3] Abstral,[4] Lazanda[5] among others[6]) is a potent opioid substance of the anilidopiperidine class. It is a strong agonist at the μ-opioid receptors and approximately 40 to 50 times more potent than pharmaceutical grade (i.e. 100% pure) heroin[7][8] and roughly 80 to 100 times more potent than morphine.&#91;citation needed&#93;\n\n                    Text: \n                    ↑ FENTANYL AND ANALOGUES | http://livertox.nih.gov/FentanylAndAnalogues.htm\n\n↑ Subsys (fentanyl sublingual spray), CenterWatch\n\n↑ INSYS Therapeutics Inc (2013), Open-label Multi-center Safety Trial of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain, clinicaltrials.gov\n\n↑ Narcotic Drugs Report 2014, UN | https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2014/Narcotic_Drugs_Report_2014.pdf\n\n↑ DEA: Deaths from fentanyl-laced heroin surging\n\n↑ Sidner, R. E., Sara (2016), Prince died of accidental overdose of opioid fentanyl, medical examiner says\n\n↑ Larsen, Rikke H.; Nielsen, Flemming; Sorensen, Jens A.; Nielsen, Jesper B. (2003). \"Dermal Penetration of Fentanyl: Inter- and Intraindividual Variations\". Pharmacology and Toxicology. 93 (5): 244–248. doi:10.1046/j.1600-0773.2003.pto930508.x. ISSN 0901-9928.\n\n\n                    Context: \n                    This excerpt provides references and sources related to fentanyl, including toxicity reports, overdose data, dermal penetration studies, and adverse event reports, supporting the document's detailed coverage of fentanyl's risks, pharmacology, and safety considerations. It emphasizes the substance's potency, overdose potential, and the importance of harm reduction.\n                "}
{"metadata": {"source": "psychonaut", "title": "Oxycodone - PsychonautWiki", "description": "Oxycodone (also known under brand names including Roxicodone, OxyContin, Percocet, Oxecta, OxyIR, Endone, Oxynorm, and OxyNEO) is a semi-synthetic opioid synthesized from poppy-derived thebaine. It is a narcotic analgesic within the morphinan chemical class and is generally indicated for relief of moderate to severe pain. It was developed in 1916 in Germany[2][3] as one of several new semi-synthetic opioids in an attempt to improve on the existing opioids.[4]", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/Oxycodone", "drug": "Oxycodone", "cid": 5284603, "char_count": 20642, "word_count": 2894, "doc_id": "doc_88", "num_chunks": 28, "chunk_id": "88::chunk_25", "document_index": 88, "latency_s": 0.5753269999986514, "prompt_toks": 5623, "completion_toks": 46, "relevance_score": 9.028039e-05}, "content": "Drug: Oxycodone | cid: 5284603\nSource: psychonaut | Source description: Oxycodone (also known under brand names including Roxicodone, OxyContin, Percocet, Oxecta, OxyIR, Endone, Oxynorm, and OxyNEO) is a semi-synthetic opioid synthesized from poppy-derived thebaine. It is a narcotic analgesic within the morphinan chemical class and is generally indicated for relief of moderate to severe pain. It was developed in 1916 in Germany[2][3] as one of several new semi-synthetic opioids in an attempt to improve on the existing opioids.[4]\n\n                    Text: \n                    ↑ Why Heroin Relapse Often Ends In Death - Lauren F Friedman (Business Insider) | http://www.businessinsider.com.au/philip-seymour-hoffman-overdose-2014-2\n\n↑ Siegel, S., Hinson, R. E., Krank, M. D., McCully, J. (23 April 1982). \"Heroin \"Overdose\" Death: Contribution of Drug-Associated Environmental Cues\". Science. 216 (4544): 436–437. doi:10.1126/science.7200260. ISSN 0036-8075.\n\n↑ 10.0 10.1 Ershad, M., Cruz, M. D., Mostafa, A., Mckeever, R., Vearrier, D., Greenberg, M. I. (March 2020). \"Opioid Toxidrome Following Grapefruit Juice Consumption in the Setting of Methadone Maintenance\". Journal of Addiction Medicine. 14 (2): 172–174. doi:10.1097/ADM.0000000000000535. ISSN 1932-0620.\n\n↑ VI.8a Convention for limiting the Manufacture and regulating the Distribution of Narcotic Drugs. Geneva, 13 July 1931 | https://treaties.un.org/doc/Treaties/1931/07/19310713%2006-44%20AM/Ch_VI_8_ap.pdf\n\n\n                    Context: \n                    This excerpt provides references and citations related to the dangers of heroin overdose, environmental factors influencing overdose risk, and international drug treaties, highlighting legal regulations and the complexities of opioid-related fatalities discussed in the full document on oxycodone.\n                "}
{"metadata": {"source": "pubchem", "title": "Lysergide | C20H25N3O | CID 5761 - PubChem", "description": "Lysergide | C20H25N3O | CID 5761 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5761", "drug": "LSD", "cid": 5761, "char_count": 139518, "word_count": 18803, "doc_id": "doc_32", "num_chunks": 193, "chunk_id": "32::chunk_110", "document_index": 32, "latency_s": 1.1401541000086581, "prompt_toks": 36471, "completion_toks": 67, "relevance_score": 6.8683185e-05}, "content": "Drug: LSD | cid: 5761\nSource: pubchem | Source description: Lysergide | C20H25N3O | CID 5761 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Daily ingestion is almost impossible because it produces an absurd \"good trip\" or high, making chronic daily misuse of LSD difficult. The dependence on LSD, therefore, is not from physical effects or cravings but psychological dependence or need. Patients want to keep re-experiencing the same good trips. There are concerns about increased antisocial behavior and abuse with unsupervised use of LSD. There also are concerns about the negative implications of increased suggestibility. There are possible dangers of creating false memories or instilling wrong beliefs.\n\n12.1.7 Acute Effects\n\n12.1.8 Toxicity Data\n\nEstimates for the lethal dosage (LD50) of LSD range from 200 ug/kg to more than 1 mg/kg of human body mass, though most sources report that there are no known human cases of such an overdose.\n\n12.1.9 Treatment\n\n\n                    Context: \n                    This section summarizes the challenges of chronic LSD misuse, emphasizing psychological dependence rather than physical effects, and highlights the wide range of estimated lethal dosages (LD50) with no confirmed human overdoses. It also briefly outlines treatment approaches for LSD toxicity. This information is crucial for understanding LSD's toxicity profile, dependency potential, and medical management.\n                "}
